Search company, investor...


Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$17M | 22 yrs ago

About Cognetix

Cognetix is a biopharmaceutical company that is developing peptide therapeutics for the treatment of epilepsy, pain and anesthesia. The company's research and development efforts are focused on conopeptides which are peptides derived from the venom of predatory sea snails. Per the company, Cognetix has corporate collaborations in place with Medtronic, Inc. and Elan Corporation plc.

Headquarters Location

421 Wakara Way Suite 201

Salt Lake City, Utah, 84108,

United States


Missing: Cognetix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cognetix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cognetix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cognetix is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cognetix Patents

Cognetix has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Conus, Nicotinic antagonists, Nicotinic agonists, Quaternary ammonium compounds, Peptides


Application Date


Grant Date



Related Topics

Conus, Nicotinic antagonists, Nicotinic agonists, Quaternary ammonium compounds, Peptides



Latest Cognetix News

Accelmed fattening Cognetix for sale

Oct 2, 2017

Accelmed fattening Cognetix for sale Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition. US urology company Cogentix Medical , controlled by Lewis Pell and Accelmed , which in turn is controlled by its founders Dr. Uri Geiger and Mori Arkin, has bought a stake in Israeli company Vensica Medical . Cogentix will initially invest $2 million, with an option to acquire the entire company for $8 million. RELATED ARTICLES Cogentix markets medical equipment for the urology market, including a device for electrical stimulation of the bladder. Vensica is developing an ultrasound device that improves penetration by drugs of the bladder walls. The product is in the animal trials phase. Listed at a $155 million market cap, Cogentix is the latest company in the portfolio of Accelmed, which acquires US public companies with an existing product and poor growth, and adds to them additional new products in need of a sales apparatus. US company EndoChoice Holdings, for example, a gastroenterology company, acquired an Israeli product, and was then sold to Boston Scientific for double the value at which Accelmed bought it. Accelmed now hopes to repeat the process in the urology sector with Cogentix, and is hoping for an even better return. When acquired by Accelmed a year ago, Cogentix had two products on the market (a device for treatment of overactive bladder syndrome by electrical stimulation of the bladder, and a sterile urological endoscope), but also a $25 million debt. The debt was to Lewis Pell, known to the Israeli medical industry as a former investor in medical device companies in cooperation with Prof. Shlomo Ben-Haim. In a combined deal, Accelmed invested $25 million in the company, and Pell converted the debt into shares in the company. Accelmed currently owns 26.7% of Cogentix, and Pell 33%. Cogentix has acquired a UK and a French company since that deal, and has successfully withstood an attack by medical device company Medtronic, which sought to compete with Cogentix's bladder stimulation product. Medtronic recently announced that it was downsizing its activity in this sector. Cogentix's share price is currently 65% higher than the price at which Accelmed made its investment. Vensica, a graduate of the Trendlines incubator, provides a delivery platform for drugs for treating urological cancer and overactive bladder syndrome. Israeli medical sector investors became aware of these sectors because of Israeli company UroGen Pharma (Nasdaq: URGN ), which operates in the same market and has a $410 million market cap. Prof. Arie Belldegrun, who recently sold Kite Pharma for $12 billion, is chairman of UroGen, and the most prominent Israeli investors in the company are the Pontifax fund and Arkin Holdings, meaning that Mori Arkin is betting on two different horses in this market. UroGen is more advanced in the field at present, but Vensica founder and CEO Avner Geva says, "The treatments are different and the market is huge; there is room in it for two companies." While Vensica actively inserts the drug into the bladder wall, UroGen has developed a system that keeps the drug longer in the bladder, and therefore eventually achieves better penetration than the currently existing products. Accelmed partner Geiger told "Globes" that Congentix was planning to establish a development center in Israel, adding that more acquisitions would be made in the coming quarters. Published by Globes [online], Israel Business News - - on October 2, 2017 © Copyright of Globes Publisher Itonut (1983) Ltd. 2017

Cognetix Frequently Asked Questions (FAQ)

  • When was Cognetix founded?

    Cognetix was founded in 1996.

  • Where is Cognetix's headquarters?

    Cognetix's headquarters is located at 421 Wakara Way, Salt Lake City.

  • What is Cognetix's latest funding round?

    Cognetix's latest funding round is Unattributed VC.

  • How much did Cognetix raise?

    Cognetix raised a total of $17M.

  • Who are the investors of Cognetix?

    Investors of Cognetix include Pappas Ventures, RBC Capital Partners, MDS Pharma Services, Zesiger Capital Group and Spice Private Equity.

  • Who are Cognetix's competitors?

    Competitors of Cognetix include Apitope, AM-Pharma, Bloomage BioTech, TheraVasc, BrainCells and 12 more.

Compare Cognetix to Competitors

Traxion Therapeutics

Traxion Therapeutics Inc. is a biotech company focused on the development of drugs for the treatment of intractable pain, specifically neuropathic pain. Traxion has assembled a portfolio of small molecule products to address this market opportunity. These products use more selective, mechanism-based approaches which exploit recent scientific discoveries in order to develop what Traxion believes are more effective, better tolerated treatments for neuropathic pain.

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Cizzle Biotechnology Logo
Cizzle Biotechnology

Cizzle Biotechnology Ltd are a biotechnology company developing gene-based strategies for the treatment and diagnosis of lung cancer.nCizzle Biotechnology Ltd is a spin-out company from the University of York, established in 2005 with support from the Bioscience Yorkshire Enterprise Fellowship program and funding from Yorkshire Forward.


Galenea is a biopharmaceutical company discovering and developing drugs to treat schizophrenia and other central nervous system diseases. The company has developed technology, the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, which enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells. The company is using the MANTRA system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.

PA Bio

Pennsylvania is home to the continuum of the biosciences - basic research, emerging companies, mature industry and global pharmaceuticals. Through Pennsylvania Bio these organizations interact to create a vibrant community. It is through the interactivity of this continuum that bioscience companies are spawned, are able to attract experienced managers and a talented workforce, and are able to grow and partner for advancement. It's all part of the company's mission: to be the catalyst to ensure Pennsylvania is engaged in biosciences by developing a cohesive community that unites the region's biotechnology, pharmaceutical, research and financial strengths.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.